[Federal Register Volume 62, Number 157 (Thursday, August 14, 1997)]
[Notices]
[Page 43539]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-21571]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of public advisory 
committees of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committees: Joint meeting of the Nonprescription Drugs 
Advisory Committee and Pulmonary-Allergy Drugs Advisory Committee.
    General Function of the Committees: To provide advice and 
recommendations to the agency on FDA regulatory issues.
    Date and Time:  The meeting will be held on September 19, 1997, 
8:30 a.m. to 5 p.m.
    Location: Holiday Inn, Ballroom, Two Montgomery Village Ave., 
Gaithersburg, MD.
    Contact Person:  Andrea G. Neal or Leander B. Madoo, Center for 
Drug Evaluation and Research (HFD-21), Food and Drug Administration, 
5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), codes 12541 and 12545. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda:  The committees will jointly consider new drug application 
(NDA) 20-840, Beconase Allergy Nasal Spray (belcomethasone 
dipropionate 0.042%, monohydrate, Glaxo Wellcome, Inc.) for over-the-
counter treatment and prevention of the symptoms of seasonal allergic 
rhinitis in patients 12 years of age and older.
    Procedure:  Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by September 5, 
1997. Oral presentations from the public will be scheduled between 
approximately 8:30 a.m. to 9:30 a.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before September 5, 
1997, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 7, 1997.
William B. Schultz,
Acting Lead Deputy Commissioner for the Food and Drug Administration.
[FR Doc. 97-21571 Filed 8-13-97; 8:45 am]
BILLING CODE 4160-01-F